The new medication Strattera, introduced in the winter of 2003, can also be helpful.

NPR: Excerpt: 'Delivered from Distraction'

The nonstimulant amantadine has been used to great advantage in treating ADD, as has bupropion (Wellbutrin) and the newest nonstimulant, Strattera.

NPR: Excerpt: 'Delivered from Distraction'

Lilly has another promising brain drug nearing the end of its development as well: Strattera, a non-stimulant treatment for attention-deficit disorder.

FORBES: Eli Lilly Goes Back To The Brain

Strattera, a nonstimulant treatment for attention deficit disorder, and osteoporosis drug Forteo have both been approved by the FDA and launched in the past few months.

FORBES: Lilly's And Schering's Blockbuster Hangovers

That could lead to more delays, says Hazlett, but right now he expects both Strattera and Cymbalta to receive final approval in the second quarter of 2003.

FORBES: Magazine Article

The FDA issued a conditional approval for Strattera on Aug. 14 but said that some new clinical studies might be needed to get the drug on the market.

FORBES: Magazine Article

And Eli Lilly (nyse: LLY - news - people ) announced a bolded warning for its attention deficit disorder treatment, Strattera, saying the treatment causes jaundice.

FORBES: Pfizer's Heart Attack

Like Strattera, it is not a controlled substance.

NPR: Excerpt: 'Delivered from Distraction'